Casana Closes $30 Million Series B Funding to Accelerate Development of Novel Effortless Home Health Monitoring
21 janv. 2022 12h15 HE | Casana Care, Inc.
ROCHESTER, N.Y., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Casana, a healthcare technology firm that is reinventing in-home health monitoring, announced today that it has raised $30 million in Series B...
Madrigal logo.jpg
Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer
10 janv. 2022 08h00 HE | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases,...
researchdrivelogo.jpg
Opportunities: Computer-aided Drug Discovery Market Expected to Gather a Revenue of $7,914.2 Million by 2028, Growing at a CAGR of 15% from 2021 to 2028 [224-Pages] | Business study by Research Dive
04 janv. 2022 09h00 HE | Research Dive
New York, USA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Research Dive has added a new report to its offering titled, “Computer-aided Drug Discovery Market by Type (Structure-based Drug Design (SBDD),...
Esperion Logo (primary).png
Esperion Appoints Benjamin O. Looker as General Counsel
04 janv. 2022 08h00 HE | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced the appointment of Benjamin O. Looker as general counsel as of January 1, 2022. Mr. Looker will serve as...
Madrigal logo.jpg
Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
30 déc. 2021 08h00 HE | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind,...
Madrigal logo.jpg
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
23 nov. 2021 07h00 HE | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and...
Madrigal logo.jpg
Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digital Experience 2021
12 nov. 2021 08h00 HE | Madrigal Pharmaceuticals, Inc.
This final read-out of the 52-week open-label resmetirom 100 mg treatment study of 171 patients with presumed non-alcoholic steatohepatitis (NASH) and fibrosis, identified using non-invasive tests,...
Esperion Logo (primary).png
Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021
12 nov. 2021 07h00 HE | Esperion Therapeutics, Inc.
- Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid (BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin (≥ 30%) in nearly 1 out of 3 of...
Esperion Logo (primary).png
Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021
01 nov. 2021 16h01 HE | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021...
TIP_link_300x300.jpg
Cardiometabolic Diseases Market Size ($121,804.49Mn by 2028) Lead by Cardiovascular Disease (3.9% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
29 oct. 2021 09h54 HE | The Insight Partners
New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cardiometabolic Diseases Market: Key InsightsAccording to our new research study on Cardiometabolic Diseases Market Size and Forecast to 2028 - COVID-19...